foxo4-dri senolytic peptide study UK | Research Frontiers | Senolytic Peptide FOXO4-DRI

Many patients notice improved recovery time, reduced soreness, and better energy levels within 24 weeks of starting treatment

The Solution: Semax

Disclaimer: All products referenced by Licensed Peptides are intended exclusively for laboratory research purposes

BPC 157 can enhance the expression and endocytosis of VEGFR2, and subsequently the phosphorylation of AKT and eNOS as proved in our previous study 6

week-0 baseline

It is unlawful to sell any peptides for a therapeutic purpose unless licensed or otherwise authorised under the Act to do so. Medsafe and Customs both confirmed to Re: News that peptides without a prescription identified at the border are destroyed